Related references
Note: Only part of the references are listed.Improving combination cancer therapy: the CombiPlex((R)) development platform
Anthony W. Tolcher et al.
FUTURE ONCOLOGY (2018)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation
Max J. Gordon et al.
LEUKEMIA RESEARCH (2017)
Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review
Andreu Porta-Sanchez et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Anthracycline Chemotherapy and Cardiotoxicity
John V. McGowan et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management
Giuseppe Curigliano et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine: daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML
Jorge E. Cortes et al.
CANCER (2015)
Biomarkers for the early detection of anthracycline-induced cardiotoxicity: current status
Jan M. Horacek et al.
BIOMEDICAL PAPERS-OLOMOUC (2014)
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
Jeffrey E. Lancet et al.
BLOOD (2014)
Prevention of Anthracycline-Induced Cardiotoxicity
Pimprapa Vejpongsa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
E. J. Feldman et al.
LEUKEMIA RESEARCH (2012)
Determination of total and encapsulated drug pharmacokinetics for CPX-351, a nanoscale liposomal fixed molar ratio of cytarabine-daunorubicin (Cyt:Daun)
Travis Ciofani et al.
CANCER RESEARCH (2011)
First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Eric J. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Historical Perspective of Anthracycline Cardiotoxicity
Michael S. Ewer et al.
HEART FAILURE CLINICS (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial
Alan K. Burnett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
Paul Tardi et al.
LEUKEMIA RESEARCH (2009)
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
F. J. F. Broeyer et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Cardiac safety of pegylated liposomal doxorubicin (Doxil((R))/Caelyx((R))) demonstrated by endomyocardial biopsy in patients with advanced malignancies
AA Gabizon et al.
CANCER INVESTIGATION (2004)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
G Batist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
